A milestone moment for immunotherapy in Europe — pembrolizumab, one of the most widely used immune checkpoint inhibitors, can now be given under the skin rather than through an IV drip. This marks a major shift in cancer care, making treatments faster, more flexible, and potentially more patient-friendly. But here’s where it gets interesting: will this convenient method redefine how cancer drugs are delivered across Europe?
The European Commission has officially granted approval for the subcutaneous (SC) form of pembrolizumab (co-formulated with berahyaluronidase alfa and marketed as Keytruda SC) for all adult indications already approved for its intravenous (IV) version. This green light follows comprehensive evidence confirming that the new administration route matches the IV form in both effectiveness and safety.
Groundbreaking Proof from the Phase 3 Trial
Backing this decision was data from the pivotal Phase 3 3475A-D77 study (NCT05722015), which compared subcutaneous and intravenous administration of pembrolizumab in patients with metastatic non–small cell lung cancer (NSCLC). The numbers tell a compelling story: patients receiving the SC version (n = 251) achieved an overall response rate (ORR) of 45% (95% CI, 39%–52%), while those receiving the IV version (n = 126) had an ORR of 42% (95% CI, 33%–51%).
Progression-free survival (PFS) and overall survival (OS) outcomes were nearly identical between both treatment groups, reinforcing that the subcutaneous route is clinically noninferior. Even pharmacokinetic data supported this finding, with a geometric mean ratio (GMR) for exposure (AUC0–6 weeks) of 1.14 (96% CI, 1.06–1.22; P < .0001) and a steady-state trough concentration GMR of 1.67 (94% CI, 1.52–1.84; P < .0001).
A Faster, More Flexible Option for Patients
“Subcutaneous pembrolizumab is the first and only immune checkpoint inhibitor in Europe that can be administered in as little as one minute every three weeks — or two minutes every six weeks,” announced Dr. Marjorie Green, Senior Vice President and Head of Oncology and Global Clinical Development at Merck Research Laboratories. She emphasized that this innovation not only shortens treatment time but also broadens where therapy can be given — from major hospitals to smaller community clinics.
Subcutaneous delivery works by injecting medication under the skin rather than directly into a vein. The method significantly reduces infusion time and bypasses the need for IV access — a huge relief for patients with difficult-to-locate veins or those who struggle with long infusion sessions.
Why It Matters
Beyond efficiency, this approval represents a shift toward patient-centered oncology care. It gives individuals more control over where and how they receive therapy, easing the burden on infusion centers and healthcare staff. However, some experts raise questions: could quicker treatments risk reduced monitoring during administration? And will the convenience of subcutaneous dosing influence how oncologists schedule combination therapies in the future?
Key Takeaways
- The European Commission has approved subcutaneous pembrolizumab (Keytruda SC) for all adult indications of the IV form across the EU.
- Phase 3 data demonstrated noninferior efficacy between SC and IV forms, with nearly equivalent response and survival rates.
- Subcutaneous administration provides greater convenience and accessibility, enabling use in broader clinical settings.
Inside the 3475A-D77 Trial Design
The 3475A-D77 study was a multicenter, randomized, open-label trial comparing subcutaneous and intravenous pembrolizumab in adults with histologically or cytologically confirmed metastatic squamous or nonsquamous NSCLC. Eligible patients were at least 18 years old, had a life expectancy of at least three months, and provided tumor tissue samples for analysis.
Those excluded included patients with small cell lung cancer, prior systemic anticancer therapy for metastatic NSCLC, or recent radiotherapy (within two weeks). Participants in the SC group received 790 mg of pembrolizumab formulated with berahyaluronidase alfa, injected subcutaneously, along with platinum-doublet chemotherapy every six weeks for 18 cycles. The IV group received 400 mg of pembrolizumab via intravenous infusion with the same chemotherapy schedule.
The study’s primary objective was to assess pembrolizumab exposure and trough serum concentration between both groups to confirm noninferiority. Secondary endpoints evaluated ORR, PFS, and OS, which all aligned closely between the two treatment routes.
The Bigger Picture
This regulatory approval doesn’t just mark a scientific success — it may open the door to a new era of oncology treatment delivery. Subcutaneous immune checkpoint inhibitors could simplify logistics, reduce hospital loads, and make advanced cancer care more accessible across varying healthcare environments.
But here’s the part most people might debate: as cancer therapies become easier to deliver, will the healthcare system need to rethink monitoring standards and safety protocols for these quicker, more flexible treatments?
What’s your take — does faster automatically mean better in cancer care? Or could convenience come with hidden trade-offs? Share your perspective in the comments; this discussion could shape how future oncology innovations are embraced.
